Phosphoproteome reveals long-term potentiation deficit following treatment of ultra-low dose soman exposure in mice.

Soman, a warfare nerve agent, poses a significant threat by inducing severe brain damage that often results in death. Nonetheless, our understanding of the biological changes underlying persistent neurocognitive dysfunction caused by low dosage of soman remains limited. This study used mice to examine the effects of different doses of soman over time. Phosphoproteomic analysis of the mouse brain is the first time to be used to detect toxic effects of soman at such low or ultra-low doses, which were undetectable based on measuring the activity of acetylcholinesterase at the whole-animal level. We also found that phosphoproteome alterations could accurately track the soman dose, irrespective of the sampling time. Moreover, phosphoproteome revealed a rapid and adaptive cellular response to soman exposure, with the points of departure 8-38 times lower than that of acetylcholinesterase activity. Impaired long-term potentiation was identified in phosphoproteomic studies, which was further validated by targeted quantitative proteomics, immunohistochemistry, and immunofluorescence analyses, with significantly increased levels of phosphorylation of protein phosphatase 1 in the hippocampus following soman exposure. This increase in phosphorylation inhibits long-term potentiation, ultimately leading to long-term memory dysfunction in mice. Copyright © 2023 Elsevier B.V. All rights reserved.

Citation

Qi Long, Zhenpeng Zhang, Yuan Li, Yuxu Zhong, Hongyan Liu, Lei Chang, Ying Ying, Tao Zuo, Yong'an Wang, Ping Xu. Phosphoproteome reveals long-term potentiation deficit following treatment of ultra-low dose soman exposure in mice. Journal of hazardous materials. 2023 Oct 05;459:132211

Mesh Tags

Substances

PMID: 37572605

search → result